• Ashna Aji Haneef
• Aparna V
• Ashly S Abraham
• Irene Thomas
• Ansa Mathew

Dolutegravir/lamivudine (trade name Dovato) is a combination drug for the treatment of HIV/AIDS. It was approved for use in the United States in April 2019.[1] It contains dolutegravir, an integrase inhibitor, and lamivudine, a reverse-transcriptase inhibitor. The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs in an attempt to control HIV infection. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. Dovato is a once-daily, single-tablet, two-drug regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay, 50 mg) with the nucleoside analogue reverse transcriptase inhibitor (NRTI) lamivudine (Epivir, 300 mg). Dovato is specifically indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history. Dovato is supplied as a tablet for oral administration. Dovato is a fixed-dose combination product containing 50 mg of dolutegravir and 300 mg of lamivudine. The recommended dosage regimen in adults is one tablet taken orally once daily with or without food.

Human Immuno Deficiency Virus, Acquired Immuno Deficiency Syndrome, Highly Active Anti Retroviral Therapy,Integrase Strand Transfer Inhibitor],Nucleoside Analogue Reverse Transcriptase Inhibitor,CD4 cells,Hepatitis-B Virus.

" DOVATO (DOLUTEGRAVIR AND LAMIVUDINE TABLETS)-AN INNOVATIVE DRUG DISCOVERY IN HIV-1 TREATMENT-A REVIEW ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 6, page no.421-429, June 2019, Available :http://www.jetir.org/papers/JETIR1907P64.pdf

" DOVATO (DOLUTEGRAVIR AND LAMIVUDINE TABLETS)-AN INNOVATIVE DRUG DISCOVERY IN HIV-1 TREATMENT-A REVIEW ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 6, page no. pp421-429, June 2019, Available at : http://www.jetir.org/papers/JETIR1907P64.pdf